Budget impact of Lanifibranor
6 evidence topics · 21 sources
Summary: lanifibranor price and economic evaluations
No price, cost-effectiveness analysis, budget impact analysis, or budget impact model of lanifibranor was identified. Inventiva states that, if lanifibranor is approved, it will still need to “establish a commercially viable pricing structure” and obtain coverage and adequate reimbursement from third-party payors, that market acceptance “will depend significantly on the availability of coverage and adequate reimbursement from third-party payors”, and that it may need to conduct pharmacoeconomic studies to demonstrate cost-effectiveness.
Summary: comparator prices and their dates
- Resmetirom (Rezdiffra): wholesale acquisition cost of $4,239.38 per 30-tablet package for each strength (60, 80, and 100 mg), stated as accurate as of 10/01/2026; the same package price was stated as of 01/01/2026. At accelerated approval on March 14, 2024, the annual wholesale acquisition cost was reported as $47,400.
- Semaglutide 2.4 mg (Wegovy): list price of $1,349.02 per package. On February 24, 2026, Novo Nordisk announced that, effective January 1, 2027, the list price of Wegovy will be lowered to $675, a reduction of approximately 50%, for all doses.
- A published lifetime cost-effectiveness model used wholesale acquisition cost-based annual treatment costs of $59,268.96 for resmetirom, $16,188.24 for semaglutide, and $13,036.44 for tirzepatide.
Summary: ICER 2023 assessment of resmetirom
ICER's final evidence report (May 25, 2023) rated resmetirom “C++” compared with standard of care in NASH with F2 or F3 fibrosis. Its Markov model took a health care sector perspective with a lifetime horizon and annual cycles. At an annual placeholder price of $19,000, based on a prior early economic model developed by the manufacturer, resmetirom produced incremental cost savings of approximately $22,400 and approximately 0.60 incremental QALYs compared with standard care alone. Annual prices to reach $50,000, $100,000, $150,000, and $200,000 per QALY gained were $32,100, $39,600, $47,100, and $54,600, and the health benefit price benchmark was $39,600 to $50,100. For budget impact, ICER applied a prevalence of 1.4% to the projected 2023 to 2027 US adult population, assumed that 762,119 patients per year would initiate treatment, and estimated that 6.5% of patients could be treated over five years at the placeholder price before reaching its threshold of approximately $777 million per year; it issued an access and affordability alert. ICER's policy recommendations state that prior authorization is reasonable, that eligible patients include all patients with F2 or F3 fibrosis, that liver biopsy should not be universally required for diagnosis, and that step therapy requiring prior pioglitazone or vitamin E is not reasonable.
Summary: published cost-effectiveness results for comparators
- Njei et al. (US payer perspective, state-transition model, F2 to F3 fibrosis): semaglutide $42,200 per QALY at 5 years and $44,138 at 10 years; resmetirom $95,981 per QALY at 5 years and $107,002 at 10 years, each versus standard of care.
- McGovern et al. (US third-party payer perspective, lifetime horizon, 2025 US dollars; model developed under contract with Novo Nordisk): semaglutide 2.4 mg $19,911 per QALY gained, resmetirom 80 mg $346,810, and resmetirom 100 mg $198,607, each versus standard of care.
- Abdeen et al. (US payer perspective, Markov cohort model, lifetime horizon, F2 to F3 fibrosis): tirzepatide $42,705 per QALY, semaglutide $80,076, and resmetirom $273,445; drug price was the most influential parameter.
- Javanbakht et al. (US commercial payer perspective, funded by Madrigal Pharmaceuticals): resmetirom increased costs by US$66,764 and QALYs by 1.24 per patient, for $53,929 per QALY gained, using a daily resmetirom cost of US$52.05.
- Mahady et al. (third-party payer perspective, biopsy-proven NASH with fibrosis level 3 or greater): pioglitazone $A2748 and vitamin E $A8475 per QALY gained versus lifestyle modification alone.
- Younossi et al.: noninvasive-test screening strategies for high-risk MASLD in US primary care, with resmetirom treatment of F2 or F3 fibrosis in the model, had ICERs of $26,913 to $27,884 per QALY in type 2 diabetes and $23,265 to $24,992 per QALY in obesity.
Summary: eligible population and budget impact estimates per plan
- A calculator funded by Madrigal Pharmaceuticals estimated 1255 to 1699 resmetirom treatment-eligible adults with noncirrhotic NASH and F2 to F3 fibrosis per 1 million commercial members in years 1 to 3 after approval, using a NASH prevalence of 4.6%, a 35% proportion with noncirrhotic moderate-to-advanced fibrosis, a diagnosis rate of about 10%, and about 16% annual growth in the treatment-eligible population.
- A budget impact analysis funded by Madrigal Pharmaceuticals for a hypothetical one-million-member US private plan, using the March 2024 resmetirom wholesale acquisition cost and uptake of 4%, 8%, and 14% of treatment-eligible patients, estimated 50, 117, and 238 patients treated in years 1 to 3, a net budget impact of $2.2 to $9.5 million, and $0.19 to $0.80 per member per month.
- An NHANES 2017 to March 2020 analysis estimated that 8.3 million (95% CI 6.6 to 9.9 million) US adults met liberal and 2.3 million (95% CI 1.4 to 3.2 million) met restrictive resmetirom eligibility criteria.
Summary: health-state utility weights
- ICER 2023 model, derived from the GAIN study: 0.76 for NASH fibrosis stages 0 to 2, 0.73 for stage 3, and 0.66 for compensated cirrhosis.
- GAIN study, US respondents with biopsy-confirmed NASH: mean EQ-5D index 0.80 for early (F0 to F2) and 0.67 for advanced (F3 to F4) fibrosis.
- Abdeen et al. model inputs from an EQ-5D-5L and discrete choice experiment elicitation study: 0.671 for MASH F2 and 0.605 for MASH F3.
- ESSENCE part 1 (sponsored by Novo Nordisk): baseline mapped EQ-5D utility of approximately 0.78 in adults with MASH and F2 or F3 fibrosis.
- 883 participants with noncirrhotic MASH (62% F3): mean estimated EQ-5D of 0.851 from the CLDQ-NAFLD-based algorithm and 0.853 from the SF-36-based algorithm.
- SF-6D: 0.660 in noncirrhotic and 0.551 in cirrhotic NAFLD.